Axatilimab in Refractory/Recurrent cGVHD: A Promising Later-Line Option

Opinion
Video

Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent chronic graft-versus-host disease (cGVHD), highlighting its potential in challenging cases.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
4 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.